Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years

9 Health Care Stocks With Whale Alerts In Today's Session

Microsoft Is Now The Biggest Deadweight On S&P 500 — And Exxon Is What Nvidia Used To Be

Microsoft is the single biggest drag on the S&P 500 this year and all of the Magnificent 7 stocks are deadweight on headline returns. 

AC Immune Amended Its 2018 Agreement With Eli Lilly For Tau Aggregation Inhibitor Drugs For Alzheimer's And Other Neurodegenerative Diseases, AC Immune Will Receive CHF10M

Under this amendment, AC Immune will receive a CHF10 million upfront payment and a subsequent milestone payment with Phase 1 dosing, in addition to milestones announced in a prior amendment. AC Immune is eligible for

'Hair Loss With GLP-1s Is Real,' Ulta CEO Says As Weight Loss Drug Trend Boosts Hair, Skincare Sales

Ulta Beauty sees rising demand as GLP-1 weight-loss drug users seek hair and skincare solutions for thinning hair and reduced skin elasticity.

Healthcare, Financials ETFs Get A Mega-Cap Reset With TRUF, TRUH

A closer look at VanEck's new TRUF and TRUH ETFs, designed to deliver cleaner healthcare and financials exposure with minimal tracking error.

Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy

Major M&A deals this week include: Eli Lilly's $7.8 billion purchase of Centessa Pharmaceuticals; Meanwhile, IO Biotech goes bankrupt.

Ro Launches Eli Lilly's KwikPen, Offering Patients A More Convenient Way To Take Zepbound

Ro, the leading direct-to-patient healthcare company, today announced that it is working with Eli Lilly to launch the recently FDA-approved Zepbound® (tirzepatide) KwikPen® nationwide on its platform. The

Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh

Eli Lilly & Co shares are down Thursday despite FDA approval of its oral weight-loss drug Foundayo, as geopolitical tensions weigh on markets.

B of A Securities Maintains Buy on Eli Lilly, Raises Price Target to $1294

B of A Securities analyst Jason Gerberry maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1293 to $1294.